Developer docs
API playgroundTry for free, no card

Search company profiles

Freenome

Full company profile

uuid00002sk

Namestring
Freenome
Legal namestring
Freenome Holdings, Inc.
Websiteurl
freenome.com
Company typeenum
Private
Founded yearint
2014
Descriptiontext

Freenome is a clinical-stage biotechnology company developing blood-based multi-cancer screening tests built on a proprietary AI-powered multiomics platform. Founded in 2014 and headquartered in Brisbane, California (formerly South San Francisco), the company combines cell-free DNA (cfDNA), methylation, cell-free RNA (cfRNA), and protein biomarker assays with proprietary deep learning and machine learning classifiers to detect cancer at its earliest, most treatable stages from a standard blood draw. Freenome operates a CLIA-certified high-complexity clinical laboratory that executes its screening assays, and its platform architecture processes both tumor- and immune-derived signatures jointly rather than relying on a single analyte.

The company's flagship product is SimpleScreen CRC, a blood-based colorectal cancer screening test that completed its FDA Premarket Approval submission and was included in the American Cancer Society's updated CRC screening guideline (May 2026), with FDA approval anticipated in H2 2026. Updated clinical data showed 85% sensitivity for CRC and 22% sensitivity for advanced precancerous lesions at 90% specificity in a 966-sample study, with a 2.6-fold reduction in limit of detection versus the prior version. The pipeline also includes SimpleScreen Lung (investigational, with reported 90.7% sensitivity at 50% specificity, advancing through the PROACT LUNG registrational study targeting 20,000 participants) and a broader multi-cancer platform validated through the Vallania, Sanderson, and PREEMPT CRC studies. The Health System Solution pairs SimpleScreen testing with EHR-integrated digital health tools that automate patient identification, education, and adherence workflows for health system customers.

Freenome's commercial model is structured primarily through licensing partnerships rather than direct-to-consumer sales. Exact Sciences (now Abbott) holds exclusive U.S. commercialization rights in a deal valued up to $885 million tied to regulatory and guideline milestones, and Roche holds exclusive ex-U.S. rights in a deal valued over $200 million including a $75 million equity investment. The company also runs a direct B2B "founding partner" program with health systems and conducts biopharma biomarker collaborations. Freenome has raised approximately $1.5 billion cumulatively across multiple venture rounds and strategic Roche investments, and is pursuing a public listing via SPAC business combination with Perceptive Capital Solutions Corp (announced December 2025, S-4 declared effective June 2026, closing anticipated July 2026) to be renamed Freenome, Inc. and listed on Nasdaq under ticker FRNM.

Short descriptiontext

Freenome is a clinical-stage biotechnology company developing AI-powered blood-based multi-cancer screening tests combining cfDNA, methylation, and protein biomarkers with deep learning for early cancer detection, serving U.S. and international health systems via licensing partnerships with Exact Sciences and Roche.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersBrisbane, United States
HQ citystring
Brisbane
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
blood-based cancer detection, multiomics screening platform, cell-free DNA diagnostics, early cancer detection tests, liquid biopsy diagnostics
Industry3 codes
PRIMARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAGADAG
Proteomics & Biomarker Analytical Testing
NAICS code1 code
  • Medical Laboratories621511
SIC code1 code
  • Services-Medical Laboratories8071
Product category
Cancer Diagnostics
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model5 records
1U.S. Licensing & Commercialization (Exact Sciences)
TypeLicensing Royalties
Description

Exclusive U.S. licensing and commercialization rights granted to Exact Sciences for the blood-based colorectal cancer screening test, with deal value up to $885 million tied to regulatory and screening-guideline milestones; contingent on FDA approval (expected H2 2026).

prnewswire.com
2Ex-U.S. Licensing & Kitted Test Commercialization (Roche)
TypeLicensing Royalties
Description

Exclusive agreement with Roche to develop and commercialize 'kitted' versions of Freenome's cancer screening assays outside the U.S., with deal potentially worth over $200 million including a $75 million equity investment, R&D support, and access to Roche's SBX sequencing technology.

freenome.com
3U.S. Broad Commercialization (Abbott, forthcoming)
TypeLicensing Royalties
Description

Abbott (formerly Exact Sciences) will lead broad U.S. commercialization of SimpleScreen CRC blood-based test following expected FDA approval anticipated mid-2026.

prnewswire.com
4Health System Direct Sales (Founding Partner Program)
TypeManaged Services
Description

Direct B2B sales of cancer-specific blood-based screening (SimpleScreen CRC and lung) combined with EHR-integrated digital health tools to health system 'founding partners,' supported by a full implementation team; recurring per-test / per-program economics implied.

freenome.com
5Biopharma Biomarker / R&D Collaborations
TypeProfessional Services
Description

Research and biomarker development collaborations with pharmaceutical companies (e.g., ADC Therapeutics) using Freenome's multiomics platform for patient stratification and drug development; financial terms typically not disclosed.

freenome.com
Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 2 records shown
1SimpleScreen
Description

Freenome's blood-based cancer screening test product line, including SimpleScreen CRC (colorectal cancer blood test under FDA review).

freenome.com
+1 more record
Core offering1 text field

Freenome fundamentally develops and sells blood-based cancer screening tests built on its proprietary multiomics platform, which integrates cell-free DNA, methylation, cell-free RNA, and protein biomarker assays with advanced computational biology and machine learning to detect cancer at its earliest stages from a standard blood draw. Its lead product, SimpleScreen CRC, is a colorectal cancer screening test currently under FDA Premarket Approval review, complemented by investigational SimpleScreen Lung and an integrated Health System Solution that pairs the tests with EHR-integrated digital health tools. Revenue flows through milestone-based licensing deals with Exact Sciences (now Abbott) in the U.S. and Roche internationally, direct sales to health system founding partners, and biopharma research collaborations.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Freenome offers an AI-powered multiomics platform for early cancer detection delivered as a unified set of blood-based screening tests and integrated health system offerings. The company's core technology is the Freenome Multiomics Platform, which integrates cell-free DNA, methylation, cell-free RNA, and protein biomarker assays with proprietary deep learning and machine learning classifiers. Built on this platform, the SimpleScreen product line comprises cancer-specific blood-based screening tests, led by SimpleScreen CRC (the flagship colorectal cancer screening test, currently under FDA Premarket Approval review) and SimpleScreen Lung (an investigational lung cancer screening test in development). These tests are delivered to providers through the Freenome Health System Solution, which pairs SimpleScreen testing with EHR-integrated digital health tools to automate patient identification, education, and adherence support. Together, the Multiomics Platform, the SimpleScreen test family, and the Health System Solution form a vertically integrated offering that combines laboratory science, AI software, and clinical workflow tooling.

Product and service4 records
1SimpleScreen CRC
CategoryBlood-based cancer screening test
Description

Freenome's flagship blood-based colorectal cancer (CRC) screening test built on its multiomics platform, currently under FDA Premarket Approval review with anticipated approval in the second half of 2026. The updated version demonstrated 85% sensitivity for CRC and 22% sensitivity for advanced precancerous lesions at 90% specificity in a 966-sample validation study presented at ASCO GI 2026; the earlier PREEMPT CRC pivotal study reported 79.2% CRC sensitivity and 91.5% specificity for non-advanced colorectal neoplasia. Intended for average-risk adults aged 45-85 as a non-invasive screening alternative to colonoscopy.

2SimpleScreen Lung
CategoryBlood-based cancer screening test
Description

Investigational blood-based multiomics screening test for the early detection of lung cancer in high-risk individuals, with reported sensitivities of 90.7% at 50% specificity and 80.4% at 75% specificity across various lung cancer subtypes and all stages. Being advanced through the PROACT LUNG registrational study targeting 20,000 high-risk participants.

3Freenome Health System Solution
CategoryIntegrated diagnostic and workflow solution
Description

An end-to-end solution pairing SimpleScreen blood-based testing (for colorectal and lung cancers) with EHR-integrated digital health tools that automate patient identification, education, and adherence support using native EHR functionality to close screening gaps and streamline workflows. Offered to founding partner health systems with implementation support, co-development publication opportunities, and early access to additional cancer tests.

4Freenome Multiomics Biomarker Collaboration Service
CategoryBiopharma research and biomarker services
Description

Research and biomarker development collaborations with pharmaceutical companies using Freenome's multiomics platform for patient stratification and drug development support, including identification of patients likely to respond to specific therapeutics (e.g., ADC Therapeutics' ADCT-402 for diffuse large B-cell lymphoma).

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Direct competitor in blood-based cancer screening and liquid biopsy. Guardant's Shield test is already FDA-approved for CRC screening, directly competing with Freenome's SimpleScreen CRC, and both companies use cfDNA-based approaches with advanced computational biology for early cancer detection.

2GRAIL
TypeDirect peer
Description

Direct peer in multi-cancer early detection via blood-based screening. GRAIL's Galleri test targets multi-cancer detection from a single blood draw, overlapping directly with Freenome's long-term multi-cancer roadmap (Vallania and Sanderson studies).

TypeDirect peer
Description

Both a commercial partner (U.S. licensee for SimpleScreen CRC) and a competitor via Cologuard, the established non-invasive CRC screening stool test. Comparable as a cancer screening franchise with strong commercial infrastructure and a focus on early detection.

TypeDirect peer
Description

Peer in blood-based oncology diagnostics. Natera's Signatera is a leading tumor-informed MRD test, and its oncology franchise (previously led by Freenome's CSO Jimmy Lin) competes in adjacent liquid biopsy applications and shares a similar cfDNA-based technology foundation.

TypeEmerging player
Description

Emerging liquid biopsy company using cfDNA fragmentation patterns for cancer detection, with a comparable machine learning / deep learning approach. Rob Guigley, Freenome's CCO, was previously CCO at Delfi, indicating overlapping expertise and adjacent technology positioning.

6Thrive Earlier Detection (Exact Sciences subsidiary)
TypeEmerging player
Description

Acquired by Exact Sciences, Thrive developed blood-based multi-cancer screening tests (CancerSEEK). It represents an emerging player in the same multi-cancer early-detection space Freenome targets with its Vallania and Sanderson programs.

TypeBroad incumbent
Description

Broader diagnostics incumbent using immune-sequencing approaches (T-cell receptor profiling). Sally Howard, Freenome's SVP Regulatory, was previously VP Regulatory at Adaptive, indicating shared talent pool and overlapping regulatory pathways in novel diagnostic assays.

TypeBroad incumbent
Description

Established oncology diagnostics company with broad oncology testing services. Douglas VanOort, Freenome's board member, is the former Chairman and CEO of NeoGenomics, reflecting shared strategic perspectives on the oncology diagnostics market.

TypeBroad incumbent
Description

Broad diagnostics incumbent and Freenome's ex-U.S. commercial partner. Roche provides global infrastructure, SBX sequencing technology access, and is a strategic equity holder with board representation, while also being a broad competitor in cancer diagnostics.

TypeBroad incumbent
Description

Broad clinical laboratory incumbent and Series E investor in Freenome. Quest offers extensive cancer screening and diagnostic services infrastructure that could complement or compete with Freenome's lab-developed and FDA-approved tests.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles15 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds15 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors56 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Freenome

Cancer Diagnosticsfreenome.com

Freenome is a clinical-stage biotechnology company developing AI-powered blood-based multi-cancer screening tests combining cfDNA, methylation, and protein biomarkers with deep learning for early cancer detection, serving U.S. and international health systems via licensing partnerships with Exact Sciences and Roche.

What Freenome does

Freenome is a clinical-stage biotechnology company developing blood-based multi-cancer screening tests built on a proprietary AI-powered multiomics platform. Founded in 2014 and headquartered in Brisbane, California (formerly South San Francisco), the company combines cell-free DNA (cfDNA), methylation, cell-free RNA (cfRNA), and protein biomarker assays with proprietary deep learning and machine learning classifiers to detect cancer at its earliest, most treatable stages from a standard blood draw. Freenome operates a CLIA-certified high-complexity clinical laboratory that executes its screening assays, and its platform architecture processes both tumor- and immune-derived signatures jointly rather than relying on a single analyte.

The company's flagship product is SimpleScreen CRC, a blood-based colorectal cancer screening test that completed its FDA Premarket Approval submission and was included in the American Cancer Society's updated CRC screening guideline (May 2026), with FDA approval anticipated in H2 2026. Updated clinical data showed 85% sensitivity for CRC and 22% sensitivity for advanced precancerous lesions at 90% specificity in a 966-sample study, with a 2.6-fold reduction in limit of detection versus the prior version. The pipeline also includes SimpleScreen Lung (investigational, with reported 90.7% sensitivity at 50% specificity, advancing through the PROACT LUNG registrational study targeting 20,000 participants) and a broader multi-cancer platform validated through the Vallania, Sanderson, and PREEMPT CRC studies. The Health System Solution pairs SimpleScreen testing with EHR-integrated digital health tools that automate patient identification, education, and adherence workflows for health system customers.

Freenome's commercial model is structured primarily through licensing partnerships rather than direct-to-consumer sales. Exact Sciences (now Abbott) holds exclusive U.S. commercialization rights in a deal valued up to $885 million tied to regulatory and guideline milestones, and Roche holds exclusive ex-U.S. rights in a deal valued over $200 million including a $75 million equity investment. The company also runs a direct B2B "founding partner" program with health systems and conducts biopharma biomarker collaborations. Freenome has raised approximately $1.5 billion cumulatively across multiple venture rounds and strategic Roche investments, and is pursuing a public listing via SPAC business combination with Perceptive Capital Solutions Corp (announced December 2025, S-4 declared effective June 2026, closing anticipated July 2026) to be renamed Freenome, Inc. and listed on Nasdaq under ticker FRNM.

Freenome firmographics

Firmographics
Name
Freenome
Legal name
Freenome Holdings, Inc.
Website
https://freenome.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
251–500 employees
Short description
Freenome is a clinical-stage biotechnology company developing AI-powered blood-based multi-cancer screening tests combining cfDNA, methylation, and protein biomarkers with deep learning for early cancer detection, serving U.S. and international health systems via licensing partnerships with Exact Sciences and Roche.
Ownership category
akta.pro rank

Freenome industry classification

Industry
Product category
Cancer Diagnostics
NAICS
Medical Laboratories (621511)
SIC
Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAGADAG
Proteomics & Biomarker Analytical Testing

Keywords

  • Blood-based cancer detection
  • Multiomics screening platform
  • Cell-free DNA diagnostics
  • Early cancer detection tests
  • Liquid biopsy diagnostics

Where Freenome is headquartered

Location

Headquarters

HQ city
Brisbane
HQ country
United States
HQ region
North America

Markets served

Freenome business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. U.S. Licensing & Commercialization (Exact Sciences): Exclusive U.S. licensing and commercialization rights granted to Exact Sciences for the blood-based colorectal cancer screening test, with deal value up to $885 million tied to regulatory and screening-guideline milestones; contingent on FDA approval (expected H2 2026).
  2. Ex-U.S. Licensing & Kitted Test Commercialization (Roche): Exclusive agreement with Roche to develop and commercialize 'kitted' versions of Freenome's cancer screening assays outside the U.S., with deal potentially worth over $200 million including a $75 million equity investment, R&D support, and access to Roche's SBX sequencing technology.
  3. U.S. Broad Commercialization (Abbott, forthcoming): Abbott (formerly Exact Sciences) will lead broad U.S. commercialization of SimpleScreen CRC blood-based test following expected FDA approval anticipated mid-2026.
  4. Health System Direct Sales (Founding Partner Program): Direct B2B sales of cancer-specific blood-based screening (SimpleScreen CRC and lung) combined with EHR-integrated digital health tools to health system 'founding partners,' supported by a full implementation team; recurring per-test / per-program economics implied.
  5. Biopharma Biomarker / R&D Collaborations: Research and biomarker development collaborations with pharmaceutical companies (e.g., ADC Therapeutics) using Freenome's multiomics platform for patient stratification and drug development; financial terms typically not disclosed.

Go-to-market motion1 record

Freenome product offering

Product offering

Core offering

Freenome fundamentally develops and sells blood-based cancer screening tests built on its proprietary multiomics platform, which integrates cell-free DNA, methylation, cell-free RNA, and protein biomarker assays with advanced computational biology and machine learning to detect cancer at its earliest stages from a standard blood draw. Its lead product, SimpleScreen CRC, is a colorectal cancer screening test currently under FDA Premarket Approval review, complemented by investigational SimpleScreen Lung and an integrated Health System Solution that pairs the tests with EHR-integrated digital health tools. Revenue flows through milestone-based licensing deals with Exact Sciences (now Abbott) in the U.S. and Roche internationally, direct sales to health system founding partners, and biopharma research collaborations.

Product overview

Freenome offers an AI-powered multiomics platform for early cancer detection delivered as a unified set of blood-based screening tests and integrated health system offerings. The company's core technology is the Freenome Multiomics Platform, which integrates cell-free DNA, methylation, cell-free RNA, and protein biomarker assays with proprietary deep learning and machine learning classifiers. Built on this platform, the SimpleScreen product line comprises cancer-specific blood-based screening tests, led by SimpleScreen CRC (the flagship colorectal cancer screening test, currently under FDA Premarket Approval review) and SimpleScreen Lung (an investigational lung cancer screening test in development). These tests are delivered to providers through the Freenome Health System Solution, which pairs SimpleScreen testing with EHR-integrated digital health tools to automate patient identification, education, and adherence support. Together, the Multiomics Platform, the SimpleScreen test family, and the Health System Solution form a vertically integrated offering that combines laboratory science, AI software, and clinical workflow tooling.

Differentiator

Problem solved

Functional benefit

Brands

  • SimpleScreen: Freenome's blood-based cancer screening test product line, including SimpleScreen CRC (colorectal cancer blood test under FDA review).
  • PREEMPT CRC

Products and services

  • SimpleScreen CRC Freenome's flagship blood-based colorectal cancer (CRC) screening test built on its multiomics platform, currently under FDA Premarket Approval review with anticipated approval in the second half of 2026. The updated version demonstrated 85% sensitivity for CRC and 22% sensitivity for advanced precancerous lesions at 90% specificity in a 966-sample validation study presented at ASCO GI 2026; the earlier PREEMPT CRC pivotal study reported 79.2% CRC sensitivity and 91.5% specificity for non-advanced colorectal neoplasia. Intended for average-risk adults aged 45-85 as a non-invasive screening alternative to colonoscopy.
  • SimpleScreen Lung Investigational blood-based multiomics screening test for the early detection of lung cancer in high-risk individuals, with reported sensitivities of 90.7% at 50% specificity and 80.4% at 75% specificity across various lung cancer subtypes and all stages. Being advanced through the PROACT LUNG registrational study targeting 20,000 high-risk participants.
  • Freenome Health System Solution An end-to-end solution pairing SimpleScreen blood-based testing (for colorectal and lung cancers) with EHR-integrated digital health tools that automate patient identification, education, and adherence support using native EHR functionality to close screening gaps and streamline workflows. Offered to founding partner health systems with implementation support, co-development publication opportunities, and early access to additional cancer tests.
  • Freenome Multiomics Biomarker Collaboration Service Research and biomarker development collaborations with pharmaceutical companies using Freenome's multiomics platform for patient stratification and drug development support, including identification of patients likely to respond to specific therapeutics (e.g., ADC Therapeutics' ADCT-402 for diffuse large B-cell lymphoma).

Companies that use Freenome

Customer profile

Ideal customer profiles2 records

Freenome technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature5 records

Freenome partnerships and signals

Strategic signal

Recent moves7 records

Expansion highlights7 records

Freenome competitors and assessment

Company assessment

Direct peers

  • Guardant Health: Direct competitor in blood-based cancer screening and liquid biopsy. Guardant's Shield test is already FDA-approved for CRC screening, directly competing with Freenome's SimpleScreen CRC, and both companies use cfDNA-based approaches with advanced computational biology for early cancer detection.
  • GRAIL: Direct peer in multi-cancer early detection via blood-based screening. GRAIL's Galleri test targets multi-cancer detection from a single blood draw, overlapping directly with Freenome's long-term multi-cancer roadmap (Vallania and Sanderson studies).
  • Exact Sciences: Both a commercial partner (U.S. licensee for SimpleScreen CRC) and a competitor via Cologuard, the established non-invasive CRC screening stool test. Comparable as a cancer screening franchise with strong commercial infrastructure and a focus on early detection.
  • Natera: Peer in blood-based oncology diagnostics. Natera's Signatera is a leading tumor-informed MRD test, and its oncology franchise (previously led by Freenome's CSO Jimmy Lin) competes in adjacent liquid biopsy applications and shares a similar cfDNA-based technology foundation.

Emerging players

  • Delfi Diagnostics: Emerging liquid biopsy company using cfDNA fragmentation patterns for cancer detection, with a comparable machine learning / deep learning approach. Rob Guigley, Freenome's CCO, was previously CCO at Delfi, indicating overlapping expertise and adjacent technology positioning.
  • Thrive Earlier Detection (Exact Sciences subsidiary): Acquired by Exact Sciences, Thrive developed blood-based multi-cancer screening tests (CancerSEEK). It represents an emerging player in the same multi-cancer early-detection space Freenome targets with its Vallania and Sanderson programs.

Broad incumbents

  • Adaptive Biotechnologies: Broader diagnostics incumbent using immune-sequencing approaches (T-cell receptor profiling). Sally Howard, Freenome's SVP Regulatory, was previously VP Regulatory at Adaptive, indicating shared talent pool and overlapping regulatory pathways in novel diagnostic assays.
  • NeoGenomics: Established oncology diagnostics company with broad oncology testing services. Douglas VanOort, Freenome's board member, is the former Chairman and CEO of NeoGenomics, reflecting shared strategic perspectives on the oncology diagnostics market.
  • Roche Diagnostics: Broad diagnostics incumbent and Freenome's ex-U.S. commercial partner. Roche provides global infrastructure, SBX sequencing technology access, and is a strategic equity holder with board representation, while also being a broad competitor in cancer diagnostics.
  • Quest Diagnostics: Broad clinical laboratory incumbent and Series E investor in Freenome. Quest offers extensive cancer screening and diagnostic services infrastructure that could complement or compete with Freenome's lab-developed and FDA-approved tests.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Freenome social profiles

Digital presence

Freenome compliance and trust

Trust signal

Compliance2 records

Freenome financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Freenome leadership team

Management profile

Number of profiles

Profiles15 records

Freenome subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Freenome funding detail

Funding detail

Funding overview

Funding rounds15 records

Investors56 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Freenome M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Freenome

What does Freenome do?

Freenome fundamentally develops and sells blood-based cancer screening tests built on its proprietary multiomics platform, which integrates cell-free DNA, methylation, cell-free RNA, and protein biomarker assays with advanced computational biology and machine learning to detect cancer at its earliest stages from a standard blood draw. Its lead product, SimpleScreen CRC, is a colorectal cancer screening test currently under FDA Premarket Approval review, complemented by investigational SimpleScreen Lung and an integrated Health System Solution that pairs the tests with EHR-integrated digital health tools. Revenue flows through milestone-based licensing deals with Exact Sciences (now Abbott) in the U.S. and Roche internationally, direct sales to health system founding partners, and biopharma research collaborations.

Is Freenome a public or private company?

Freenome is a private company. It is classified as venture growth investor backed and is currently operating.

When was Freenome founded?

Freenome was founded in 2014. It employs 251 to 500 people.

Where is Freenome based?

Freenome is headquartered in Brisbane, United States, in the North America region.

How does Freenome make money?

Five revenue lines are on record. U.S. Licensing & Commercialization (Exact Sciences) is the primary driver. The others are ex-U.S. Licensing & Kitted Test Commercialization (Roche), U.S. Broad Commercialization (Abbott, forthcoming), health System Direct Sales (Founding Partner Program) and biopharma Biomarker / R&D Collaborations.

Who are Freenome's main competitors?

Direct peers on record are Guardant Health, GRAIL, Exact Sciences and Natera. Emerging players are Delfi Diagnostics and Thrive Earlier Detection (Exact Sciences subsidiary). Broad incumbents are Adaptive Biotechnologies, NeoGenomics, Roche Diagnostics and Quest Diagnostics.

Does Freenome have an API?

No public API is recorded for Freenome.

What industry is Freenome in?

Freenome's product category is Cancer Diagnostics. Its primary akta.pro industry code is HLAAALAE, Oncology Diagnostics (tumor profiling, MRD, liquid biopsy), with a secondary code of HLAAAMAC, Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays). Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Quiver QuantitativeFREENOME ($FRNM) Releases Q3 2026 Earnings, Stock Rises | FRNM Stock NewsFREENOME reported Q3 2026 earnings of $1.10 per share, beating estimates of $0.42, and revenue of $183.49 million, up from $107.98 million. The stock rose 7.26% after market close, and 13 institutional investors added shares in the quarter.Ticker ReportFreenome (NASDAQ:FRNM) Shares Up 9.3% – Time to Buy?Freenome shares rose 9.3% in mid-day trading on Tuesday, trading as high as $13.55. Analysts have a consensus rating of Moderate Buy with a $18.00 target price. The company develops blood-based cancer screening tests.YahooCathie Wood Goes Bargain Hunting: 3 Stocks She Just BoughtArk Invest's Cathie Wood added to stakes in CoreWeave, Scribe Therapeutics, and Freenome on Monday, with shares down 28-57% from highs. CoreWeave's revenue rose 113% in the latest quarter, but it remains unprofitable, while Scribe has cash to fund operations through 2029.The Motley FoolCathie Wood Goes Bargain Hunting: 3 Stocks She Just BoughtCathie Wood added to stakes in CoreWeave, Scribe Therapeutics, and Freenome on Monday, with shares down 28% to 57% from highs. CoreWeave's revenue rose 113% in the latest quarter, while Scribe has cash to fund operations through 2029. Freenome received FDA clearance for a lung cancer screening test.The Motley FoolCathie Wood Goes Bargain Hunting: 3 Stocks She Just BoughtArk Invest's Cathie Wood added stakes in CoreWeave, Scribe Therapeutics, and Freenome on Monday, all trading 28-57% below prior highs. CoreWeave's revenue rose 113% in the latest quarter, while Scribe has cash to fund operations through 2029. Freenome received FDA clearance for a lung cancer screening test.Stock TitanFreenome launches lung screening test with 85% sensitivityFreenome launched SimpleScreen Lung, a blood-based lung cancer screening test for adults 50-80 with a ≥20 pack-year smoking history. In an independent cohort, it showed 85% sensitivity at 50% specificity and a 99.8% negative predictive value. The test can be ordered alone or with the FDA-approved SimpleScreen CRC test in a single blood draw.American Banking and Market NewsFreenome (NASDAQ:FRNM) Stock Has Average Price Target of $18.00Freenome's stock has an average price target of $18.00 from six brokerages, with five buy ratings and one sell. The stock opened at $11.75, trading below its 50-day moving average of $14.94. The company develops blood-based cancer screening tests.Ticker ReportFreenome (NASDAQ:FRNM) Shares Shorted: Short Interest Up 100.4% in SeptemberShort interest in Freenome rose 100.4% to 3.4 million shares as of September 30, with 4.1% of shares sold short. Analysts have set an average price target of $18.00, with five Buy ratings and one Sell. The stock traded at $12.10 on Wednesday.MedTech DiveAbbott launches Freenome’s colorectal cancer screening testAbbott launched Freenome's SimpleScreen CRC blood-based colorectal cancer screening test in the U.S. for people who decline guideline-recommended screening. The test, FDA-approved this summer, has 81.1% sensitivity for colorectal cancer and is covered by Medicare with no out-of-pocket costs.Ticker ReportFreenome (NASDAQ:FRNM) Stock Rating Upgraded by Wall Street ZenWall Street Zen upgraded Freenome to a sell rating in a research report issued Saturday. The stock has an average rating of Moderate Buy with a consensus price target of $18.00, and shares opened at $15.99. Freenome develops blood-based cancer screening tests.